China Nepstar Chain Drug Store Eyes Quality As Quantities Grow Rapidly
This article was originally published in PharmAsia News
Nepstar says it needs to focus on retaining customer loyalty at fewer, but more productive stores, to keep strong margins even as drugs sales by volume soar in China.
You may also be interested in...
Pricing Pressures Lower Profits For Chinese Drug Chain Nepstar, While Healthcare Reform Has Opposite Effect On Hospital Chain Chindex - China Earnings Roundup (Part 1)
Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.
Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.